Live Breaking News & Updates on Development biosimilars at biogen

Stay updated with breaking news from Development biosimilars at biogen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Biogen Inc.: Biogen and Bio-Thera Solutions Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate at the Annual European Congress of Rheumatology (EULAR 2022)

CAMBRIDGE, Mass. and GUANGZHOU, China, June 03, 2022(Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today presented positive Phase 3 data for BIIB800 (BAT1806), a biosimilar candidate referencing

Guangzhou , Guangdong , China , Taiwan , Denmark , Copenhagen , Køavn- , Hong-kong , Cambridge , Cambridgeshire , United-kingdom , Macau

Samsung Bioepis Announces New Data on Adalimumab

Samsung Bioepis and Biogen to present one abstract and one poster at EULAR 2022 on adalimumab biosimilar, SB5 including Phase 1 study of a new SB5...

Denmark , Copenhagen , Køavn- , Mourad-farouk-rezk , Adalimumab-biosimilar , Yoon-kim , Donghoon-shin , Samsung-bioepi , Jane-chung , Samsung-bioepis , Development-biosimilars-at-biogen , European-congress

Investegate |Samsung Bioepis Announcements | Samsung Bioepis: Samsung Bioepis Announces New Data on Adalimumab Biosimilar, SB5 at the Annual European Congress of Rheumatology (EULAR 2022)

Investegate announcements from Samsung Bioepis, Samsung Bioepis Announces New Data on Adalimumab Biosimilar, SB5 at the Annual European Congress of Rheumatology (EULAR 2022)

Denmark , Copenhagen , Køavn- , Mourad-farouk-rezk , Yoon-kim , Adalimumab-biosimilar , Donghoon-shin , Samsung-bioepi , Jane-chung , Samsung-bioepis , Development-biosimilars-at-biogen , European-congress

Samsung Bioepis Announces New Data on Adalimumab Biosimilar, SB5 at the Annual European Congress of Rheumatology (EULAR 2022)

Samsung Bioepis and Biogen to present one abstract and one poster at EULAR 2022 on adalimumab biosimilar, SB5 including Phase 1 study of a new SB5 formulation and a pan-European real-world study, PROPER Abstract

Denmark , Copenhagen , Køavn- , Mourad-farouk-rezk , Samsung-bioepi , Samsung-bioepis , Yoon-kim , Adalimumab-biosimilar , Kostenloser-wertpapierhandel , Donghoon-shin , Jane-chung , Development-biosimilars-at-biogen